# Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Source: https://onco.cc/trials/nct06370754/  
OnCo record `nct06370754` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of liposomal irinotecan, fluorouracil (5-FU), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel), nab-paclitaxel and other drugs in pancreatic cancer, run by Fudan University, not yet recruiting.

## Summary

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment is a phase 1/2, interventional study registered as NCT06370754 by Fudan University, with a registry enrolment figure of 117 participants, started 2024-04-30 and due to reach its primary completion in 2026-04-30. Interventions recorded: JS001; JS004; JS007; JS015; Irinotecan Liposome Injection; 5-Fluorouracil (5-FU); Leucovorin (LV); Nab paclitaxel; Gemcitabine. Conditions listed: Pancreatic Cancer. Primary outcome: Incidence of dose-limiting toxicity (DLT) (phase IB); Objective Response Rate (ORR) (phase II). Pancreatic eligibility wording from the registry: "* Patients with locally advanced unresectable or metastatic pancreatic cancer confirmed by histopathology or cytopathology (islet cell tumor is not eligible for inclusion) who meet the following requirements:". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: FD-IMPACT
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06370754
- Phase: 1/2
- Setting: A Phase Ib/II Platform Trial of Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
- Sponsor: Fudan University
- Enrolled: 117

## Sources

- ClinicalTrials.gov NCT06370754: https://clinicaltrials.gov/study/NCT06370754

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Liposomal irinotecan](https://onco.cc/drugs/liposomal-irinotecan/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06370754.json